NASDAQ:CUE Cue Biopharma (CUE) Stock Price, News & Analysis $0.76 -0.02 (-2.18%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.74 -0.02 (-2.23%) As of 04/17/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Cue Biopharma Stock (NASDAQ:CUE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cue Biopharma alerts:Sign Up Key Stats Today's Range$0.75▼$0.8050-Day Range$0.62▼$1.4952-Week Range$0.45▼$2.26Volume111,540 shsAverage Volume445,031 shsMarket Capitalization$47.11 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingBuy Company OverviewCue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Read More… Cue Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreCUE MarketRank™: Cue Biopharma scored higher than 86% of companies evaluated by MarketBeat, and ranked 70th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCue Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCue Biopharma has received no research coverage in the past 90 days.Read more about Cue Biopharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cue Biopharma are expected to grow in the coming year, from ($0.76) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cue Biopharma is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cue Biopharma is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCue Biopharma has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cue Biopharma's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.53% of the float of Cue Biopharma has been sold short.Short Interest Ratio / Days to CoverCue Biopharma has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cue Biopharma has recently decreased by 0.93%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCue Biopharma does not currently pay a dividend.Dividend GrowthCue Biopharma does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.58 Percentage of Shares Shorted1.53% of the float of Cue Biopharma has been sold short.Short Interest Ratio / Days to CoverCue Biopharma has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cue Biopharma has recently decreased by 0.93%, indicating that investor sentiment is improving. News and Social Media2.9 / 5News Sentiment0.19 News SentimentCue Biopharma has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Cue Biopharma this week, compared to 1 article on an average week.Search Interest4 people have searched for CUE on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cue Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders12.26% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 35.04% of the stock of Cue Biopharma is held by institutions.Read more about Cue Biopharma's insider trading history. Receive CUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CUE Stock News HeadlinesBoehringer and Cue Biopharma to develop autoimmune therapiesApril 16 at 5:41 AM | finance.yahoo.comCue in pact with Boehringer for autoimmune and inflammatory diseasesApril 15, 2025 | msn.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 19, 2025 | Porter & Company (Ad)Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)April 15, 2025 | seekingalpha.comCue Biopharma receives $12M upfront in CUE-501 license pactApril 15, 2025 | markets.businessinsider.comCue Biopharma stock falls after pricing capital raise of $20M via securities offeringApril 15, 2025 | msn.comBoehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseasesApril 15, 2025 | globenewswire.comCue Biopharma Announces Pricing of Approximately $20 Million Public OfferingApril 14, 2025 | globenewswire.comSee More Headlines CUE Stock Analysis - Frequently Asked Questions How have CUE shares performed this year? Cue Biopharma's stock was trading at $1.09 at the beginning of the year. Since then, CUE stock has decreased by 30.1% and is now trading at $0.7620. View the best growth stocks for 2025 here. How were Cue Biopharma's earnings last quarter? Cue Biopharma, Inc. (NASDAQ:CUE) posted its quarterly earnings data on Friday, March, 28th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.01. The company had revenue of $1.80 million for the quarter, compared to the consensus estimate of $1.70 million. Cue Biopharma had a negative net margin of 468.02% and a negative trailing twelve-month return on equity of 156.38%. How do I buy shares of Cue Biopharma? Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cue Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cue Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walmart (WMT). Company Calendar Last Earnings3/28/2025Today4/19/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CUE CIK1645460 Webwww.cuebiopharma.com Phone(617) 949-2680FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$4.00 Low Stock Price Target$2.00 Potential Upside/Downside+293.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,730,000.00 Net Margins-468.02% Pretax Margin-468.02% Return on Equity-156.38% Return on Assets-88.07% Debt Debt-to-Equity Ratio0.05 Current Ratio2.22 Quick Ratio2.22 Sales & Book Value Annual Sales$9.29 million Price / Sales5.07 Cash FlowN/A Price / Cash FlowN/A Book Value$0.82 per share Price / Book0.93Miscellaneous Outstanding Shares61,819,000Free Float55,583,000Market Cap$47.11 million OptionableOptionable Beta2.02 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CUE) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cue Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.